2020
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
Reardon DA, Brandes AA, Omuro A, Mulholland P, Lim M, Wick A, Baehring J, Ahluwalia MS, Roth P, Bähr O, Phuphanich S, Sepulveda JM, De Souza P, Sahebjam S, Carleton M, Tatsuoka K, Taitt C, Zwirtes R, Sampson J, Weller M. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma. JAMA Oncology 2020, 6: 1003-1010. PMID: 32437507, PMCID: PMC7243167, DOI: 10.1001/jamaoncol.2020.1024.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalBevacizumabBrain NeoplasmsDNA Modification MethylasesDNA Repair EnzymesFemaleGlioblastomaHumansImmune Checkpoint InhibitorsMaleMiddle AgedNeoplasm Recurrence, LocalNivolumabProgrammed Cell Death 1 ReceptorTemozolomideTreatment OutcomeTumor Suppressor ProteinsYoung AdultConceptsTreatment-related adverse eventsPhase 3 clinical trialsPrimary end pointOverall survivalRecurrent glioblastomaClinical trialsMedian OSGrade 3/4 treatment-related adverse eventsRandomized phase 3 clinical trialSingle-agent PD-1 blockadeEnd pointEffects of nivolumabUnacceptable toxic effectsMedian overall survivalObjective response ratePD-1 blockadeOverall patient populationImmune checkpoint blockadeData cutoffAdverse eventsCheckpoint blockadeFirst recurrenceInhibitor therapyClinical outcomesSafety profile
2013
Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System
Raghunathan A, Wani K, Armstrong TS, Vera‐Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito‐Reyes M, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffietti R, Wu J, Miller CR, Gilbert MR, Aldape KD, Network C. Histological Predictors of Outcome in Ependymoma are Dependent on Anatomic Site Within the Central Nervous System. Brain Pathology 2013, 23: 584-594. PMID: 23452038, PMCID: PMC8028973, DOI: 10.1111/bpa.12050.Peer-Reviewed Original ResearchConceptsProgression-free survivalWorse progression-free survivalElevated mitotic rateAnatomic sitesPosterior fossaHistological featuresMicrovascular proliferationMitotic rateWorld Health Organization grade IIComposite histological scoresMultivariate Cox regressionWorse clinical outcomesSpecific histological featuresRelevant clinical variablesDetailed histological examinationClinical outcomesCox regressionSC tumorsClinical variablesHistological factorsPF tumorsGrade IIHistological scoresEpendymal canalHistological examination
2012
A prognostic gene expression signature in infratentorial ependymoma
Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffietti R, Ledoux A, Wilson C, Long L, Gilbert MR, Aldape K, For the Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. Acta Neuropathologica 2012, 123: 727-738. PMID: 22322993, PMCID: PMC4013829, DOI: 10.1007/s00401-012-0941-4.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAge FactorsAntigens, NeoplasmChildCluster AnalysisDatabases, GeneticDNA Topoisomerases, Type IIDNA-Binding ProteinsEpendymomaFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansInfratentorial NeoplasmsLongitudinal StudiesMaleOligonucleotide Array Sequence AnalysisPrognosisReproducibility of ResultsSex FactorsSurvival AnalysisYoung AdultConceptsRecurrence-free survivalInfratentorial ependymomaClinical outcomesReal-time reverse transcriptase-polymerase chain reaction assaysReverse transcriptase-polymerase chain reaction assaysGroup 1 tumorsPrognostic gene expression signaturesTranscriptase-polymerase chain reaction assaysGroup 2 tumorsGene expression subgroupsPolymerase chain reaction assaysClinical factorsGene expression signaturesIndependent predictorsPrognostic significanceInfratentorial compartmentHistological factorsClinical behaviorChain reaction assaysClinical aggressivenessPrognostic signatureExpression subgroupsEpendymomaMolecular alterationsMultivariate analysis